Journal List > Allergy Asthma Respir Dis > v.5(4) > 1059256

Kwon, Song, Kim, Lim, Yang, Jung, Lee, Suh, Shin, Kim, Kim, Lee, Cho, and The Korean Academy of Asthma, Allergy and Clinical Immunology Standardization Committee: The KAAACI Standardization Committee Report on the procedure and application of fractional exhaled nitric oxide measurement

Abstract

Fractional exhaled nitric oxide (FeNO) is a biomarker for type 2 inflammation in the airways, and its measurement has the distinct strengths of being simple, rapid, convenient, and reproducible. Since the discovery of FeNO in the 1990s, its measurement tools have been extensively developed and validated by several researchers. In particular, FeNO showed the potential to support the diagnosis of asthma and eosinophilic bronchitis. Since it has begun to be widely utilized in clinical research areas as well as daily practice, we summarized the standardized diagnostic procedures and suggested the clinical application of FeNO measurement in Korean population.

REFERENCES

1. Alving K, Malinovschi A. Basic aspects of exhaled nitric oxide. Eur Respir Monogr. 2010; 49:1–31.
crossref
2. Persson MG, Zetterstrom O, Agrenius V, Ihre E, Gustafsson LE. Single-breath nitric oxide measurements in asthmatic patients and smokers. Lancet. 1994; 343:146–7.
crossref
3. Massaro AF, Gaston B, Kita D, Fanta C, Stamler JS, Drazen JM. Expired nitric oxide levels during treatment of acute asthma. Am J Respir Crit Care Med. 1995; 152:800–3.
crossref
4. Kharitonov SA, Yates DH, Chung KF, Barnes PJ. Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients. Eur Respir J. 1996; 9:196–201.
crossref
5. Kim MY, Jo EJ, Lee SE, Lee SY, Song WJ, Kim TW, et al. Reference ranges for induced sputum eosinophil counts in Korean adult population. Asia Pac Allergy. 2014; 4:149–55.
crossref
6. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987; 84:9265–9.
crossref
7. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988; 333:664–6.
crossref
8. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell. 1994; 78:915–8.
crossref
9. Kim SH, Yoon HJ. Use of the exhaled nitric oxide for management of asthma and respiratory diseases. Korean J Med. 2008; 74:579–86.
10. Morris SM Jr, Billiar TR. New insights into the regulation of inducible nitric oxide synthesis. Am J Physiol. 1994; 266(6 Pt 1):E829–39.
crossref
11. Dweik RA, Comhair SA, Gaston B, Thunnissen FB, Farver C, Thomassen MJ, et al. NO chemical events in the human airway during the immediate and late antigen-induced asthmatic response. Proc Natl Acad Sci U S A. 2001; 98:2622–7.
crossref
12. Guo FH, Comhair SA, Zheng S, Dweik RA, Eissa NT, Thomassen MJ, et al. Molecular mechanisms of increased nitric oxide (NO) in asthma: evidence for transcriptional and post-translational regulation of NO synthesis. J Immunol. 2000; 164:5970–80.
crossref
13. Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med. 2001; 164(8 Pt 1):1376–81.
crossref
14. Warke TJ, Fitch PS, Brown V, Taylor R, Lyons JD, Ennis M, et al. Exhaled nitric oxide correlates with airway eosinophils in childhood asthma. Thorax. 2002; 57:383–7.
crossref
15. Berry MA, Shaw DE, Green RH, Brightling CE, Wardlaw AJ, Pavord ID. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy. 2005; 35:1175–9.
crossref
16. Paoliello-Paschoalato AB, Oliveira SH, Cunha FQ. Interleukin 4 induces the expression of inducible nitric oxide synthase in eosinophils. Cytokine. 2005; 30:116–24.
crossref
17. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009; 360:973–84.
crossref
18. American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005; 171:912–30.
19. Yune S, Lee JY, Choi DC, Lee BJ. Fractional exhaled nitric oxide: comparison between portable devices and correlation with sputum eosinophils. Allergy Asthma Immunol Res. 2015; 7:404–8.
crossref
20. Harnan SE, Tappenden P, Essat M, Gomersall T, Minton J, Wong R, et al. Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath. Health Technol Assess. 2015; 19:1–330.
crossref
21. de Gouw HW, Hendriks J, Woltman AM, Twiss IM, Sterk PJ. Exhaled nitric oxide (NO) is reduced shortly after bronchoconstriction to direct and indirect stimuli in asthma. Am J Respir Crit Care Med. 1998; 158:315–9.
crossref
22. Silkoff PE, Wakita S, Chatkin J, Ansarin K, Gutierrez C, Caramori M, et al. Exhaled nitric oxide after beta2-agonist inhalation and spirometry in asthma. Am J Respir Crit Care Med. 1999; 159:940–4.
23. de Gouw HW, Grunberg K, Schot R, Kroes AC, Dick EC, Sterk PJ. Relationship between exhaled nitric oxide and airway hyperresponsiveness following experimental rhinovirus infection in asthmatic subjects. Eur Respir J. 1998; 11:126–32.
crossref
24. Kharitonov SA, Yates D, Barnes PJ. Increased nitric oxide in exhaled air of normal human subjects with upper respiratory tract infections. Eur Respir J. 1995; 8:295–7.
crossref
25. Olin AC, Aldenbratt A, Ekman A, Ljungkvist G, Jungersten L, Alving K, et al. Increased nitric oxide in exhaled air after intake of a nitrate-rich meal. Respir Med. 2001; 95:153–8.
crossref
26. Bruce C, Yates DH, Thomas PS. Caffeine decreases exhaled nitric oxide. Thorax. 2002; 57:361–3.
crossref
27. Byrnes CA, Dinarevic S, Busst CA, Shinebourne EA, Bush A. Effect of measurement conditions on measured levels of peak exhaled nitric oxide. Thorax. 1997; 52:697–701.
crossref
28. Kharitonov SA, Robbins RA, Yates D, Keatings V, Barnes PJ. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med. 1995; 152:609–12.
crossref
29. Bergeron C, Boulet LP, Page N, Laviolette M, Zimmermann N, Rothen-berg ME, et al. Influence of cigarette smoke on the arginine pathway in asthmatic airways: increased expression of arginase I. J Allergy Clin Immunol. 2007; 119:391–7.
30. Robbins RA, Millatmal T, Lassi K, Rennard S, Daughton D. Smoking cessation is associated with an increase in exhaled nitric oxide. Chest. 1997; 112:313–8.
crossref
31. Terada A, Fujisawa T, Togashi K, Miyazaki T, Katsumata H, Atsuta J, et al. Exhaled nitric oxide decreases during exercise-induced bronchoconstriction in children with asthma. Am J Respir Crit Care Med. 2001; 164(10 Pt 1):1879–84.
crossref
32. Bisgaard H, Loland L, Oj JA. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. 1999; 160:1227–31.
33. Davis BE, Illamperuma C, Gauvreau GM, Watson RM, O'Byrne PM, De-schesnes F, et al. Single-dose desloratadine and montelukast and allergen-induced late airway responses. Eur Respir J. 2009; 33:1302–8.
crossref
34. Montuschi P, Mondino C, Koch P, Ciabattoni G, Barnes PJ, Baviera G. Effects of montelukast treatment and withdrawal on fractional exhaled nitric oxide and lung function in children with asthma. Chest. 2007; 132:1876–81.
crossref
35. Fardon TC, Lee DK, Hodge MR, Lipworth BJ. Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma. Ann Allergy Asthma Immunol. 2005; 95:259–65.
crossref
36. Lim S, Tomita K, Caramori G, Jatakanon A, Oliver B, Keller A, et al. Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am J Respir Crit Care Med. 2001; 164:273–6.
crossref
37. Song WJ, Kwon JW, Kim EJ, Lee SM, Kim SH, Lee SY, et al. Clinical application of exhaled nitric oxide measurements in a korean population. Allergy Asthma Immunol Res. 2015; 7:3–13.
crossref
38. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011; 184:602–15.
crossref
39. Jo EJ, Song WJ, Kim TW, Park HW, Chang YS, Kim TB, et al. Reference ranges and determinant factors for exhaled nitric oxide in a healthy korean elderly population. Allergy Asthma Immunol Res. 2014; 6:504–10.
crossref
40. McGrath KW, Icitovic N, Boushey HA, Lazarus SC, Sutherland ER, Chinchilli VM, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med. 2012; 185:612–9.
crossref
41. Song WJ, Kim HJ, Shim JS, Won HK, Kang SY, Sohn KH, et al. Diagnostic accuracy of fractional exhaled nitric oxide measurement in predicting cough-variant asthma and eosinophilic bronchitis in adults with chronic cough: A systematic review and metaanalysis. J Allergy Clin Immunol 2017 Jan 11 [Epub]. pii: S0091-6749(17)30006-4.https://doi.org/10.1016/j.jaci.2016.11.037.
42. Karrasch S, Linde K, Rucker G, Sommer H, Karsch-Volk M, Kleijnen J, et al. Accuracy of FENO for diagnosing asthma: a systematic review. Thorax. 2017; 72:109–16.
43. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000; 161:309–29.
44. Woo SI, Lee JH, Kim H, Kang JW, Sun YH, Hahn YS. Utility of fractional exhaled nitric oxide F E NO measurements in diagnosing asthma. Respir Med. 2012; 106:1103–9.
45. Park SH, Kim DH, Koh YI. Usefulness of fractional exhaled nitric oxide for the diagnosis of asthma and its assessment of asthma control. Korean J Asthma Allergy Clin Immunol. 2012; 32:83–91.
46. Mattes J, Storm van's Gravesande K, Reining U, Alving K, Ihorst G, Hen-schen M, et al. NO in exhaled air is correlated with markers of eosinophilic airway inflammation in corticosteroid-dependent childhood asthma. Eur Respir J. 1999; 13:1391–5.
crossref
47. Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax. 1998; 53:91–5.
crossref
48. Jones SL, Kittelson J, Cowan JO, Flannery EM, Hancox RJ, McLachlan CR, et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am J Respir Crit Care Med. 2001; 164:738–43.
crossref
49. Korevaar DA, Westerhof GA, Wang J, Cohen JF, Spijker R, Sterk PJ, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and metaanalysis. Lancet Respir Med. 2015; 3:290–300.
crossref
50. Kim YH, Kim KW, Baek J, Park HB, Kim H, Song KJ, et al. Usefulness of impulse oscillometry and fractional exhaled nitric oxide in children with Eosinophilic bronchitis. Pediatr Pulmonol. 2013; 48:221–8.
crossref
51. Chaudhuri R, McMahon AD, Thomson LJ, MacLeod KJ, McSharry CP, Livingston E, et al. Effect of inhaled corticosteroids on symptom severity and sputum mediator levels in chronic persistent cough. J Allergy Clin Immunol. 2004; 113:1063–70.
crossref
52. Song WJ, Won HK, Moon SD, Chung SJ, Kang SY, Sohn KH, et al. Could fractional exhaled nitric oxide test be useful in predicting inhaled corticosteroid responsiveness in chronic cough? A systematic review. J Allergy Clin Immunol Pract. 2017; 5:135–43.e1.
crossref
53. Oh MJ, Lee JY, Lee BJ, Choi DC. Exhaled nitric oxide measurement is useful for the exclusion of nonasthmatic eosinophilic bronchitis in patients with chronic cough. Chest. 2008; 134:990–5.
crossref

Fig. 1.
Distribution of fractional exhaled nitric oxide (FeNO) levels in community based adult population and its comparison with asthma patients in Korea. Males (A) and females (B). ppb, parts per billion. Reprinted from Allergy Asthma Immunol Res 2014;6:504-10.39
aard-5-185f1.tif
Table 1.
Factors affecting fractional exhaled nitric oxide levels
Factor
Increased
 Bronchodilator
 Respiratory tract infection
 Nitrate-rich diet
Decreased
 Bronchoconstriction
 Spirometric maneuver
 Corticosteroid, antileukotrienes
 Water, coffee intake
 Cigarette smoke
 Exercise
Table 2.
Summary of diagnostic accuracy meta-analyses on fractional exhaled nitric oxide tests to predict asthma
Study Population Summary AUC (95% CI) Sensitivity (95% CI) Specificity (95% CI)
Karrasch et al. (2017)42 Patients with symptoms suggestive of asthma 0.80 (0.77–0.85) 65% (58–72) 82% (76–86)
Song et al. (2017)41 Patients with chronic cough 0.87 (0.83–0.89) 72% (61–81) 85% (81–88)

AUC, area under the curve; CI, confidence interval.

Table 3.
Summary of diagnostic accuracy studies on fractional exhaled nitric oxide tests to predict asthma in Korean populations
Study Population Demographic Cutoff value Sensitivity Specificity
Park et al. (2012)45 Patients with recurrent cough, dyspnea or wheeze (n=161) Adults (mean, 43 yr) 25.5 ppb 57.1% 75.7%
Jo et al. (2014)39 Community-based general adult population (n=570) vs. patients with asthma (n=74) Adults (mean, 59 yr) Male, 30.5 ppb; female, 20.5 ppb Male, 70%; female, 79.5% Male, 90%; female, 86.9%
Woo et al. (2014)44 Patients with recurrent cough, dyspnea, or wheeze (n=245) Children (8–16 yr) 22 ppb 56.9% 87.2%

ppb, parts per billion.

Table 4.
Summary of diagnostic accuracy meta-analyses on fractional exhaled nitric oxide to predict eosinophilic airway inflammation
Study Population Summary AUC (95% CI) Sensitivity (95% CI) Specificity (95% CI)
Korevaar et al. (2015)49 Patients with asthma Adults, 0.75 (0.72–0.78); Children, 0.81 (0.72–0.89) Adults, 66% (57–75); Children, 72% (24–95) Adults, 76% (65–85); Children, 77% (20–98)
Song et al. (2017)41 Patients with nonasthmatic chronic cough 0.81 (0.77–0.84) 72% (62–80) 83% (73–90)

AUC, area under the curve; CI, confidence interval.

Table 5.
Summary of diagnostic accuracy studies on fractional exhaled nitric oxide tests to predict eosinophilic airway inflammation in Korean populations
Study Population Demographics Cutoff values Sensitivity Specificity
Oh et al. (2008)53 Patients with cough >3 wk (n=211) Adults (mean, 46 yr) 31.7 ppb 86% 76%
Yune et al. (2015)19 Patients with symptoms suggestive of asthma (n=40) Adults (mean, 53 yr) 37.5 ppb 90% 81%

ppb, parts per billion.

Table 6.
Clinical application of fractional exhaled nitric oxide tests in asthma patients with current respiratory symptoms
Fractional exhaled nitric oxide values Allergic airway inflammation Consideration
>50 ppb (in adults)>35 ppb (in children) Likely Increase inhaled corticosteroids Check inhaler errors Check adherence Control allergen exposure (if patients have allergic asthma) Consider corticosteroid-resistant eosinophilic asthma
25–50 ppb (in adults) 20–35 ppb (in children) Possible; cautious interpretation is recommended. Increase inhaled corticosteroids Check inhaler errors Check adherence Control allergen exposure (if patients have allergic asthma)
<25 ppb (in adults) <20 ppb (in children) Less likely Review asthma diagnosis Consider noneosinophilic asthma Consider comorbid diseases like rhinosinusitis, gastroesophageal reflux diseases, or cardiac diseases

ppb, parts per billion.

TOOLS
Similar articles